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Gene expression in intestinal mucosal biopsy
specimens obtained from dogs with chronic
enteropathy
Vicki L. Wilke, DVM, PhD; Dan Nettleton, PhD; Meghan J. Wymore, DVM; Jack M. Gallup, MS;
Cumhur Yusuf Demirkale, PhD; Mark R. Ackermann, DVM, PhD; Chris K. Tuggle, PhD;
Amanda E. Ramer-Tait, PhD; Michael J. Wannemuehler, PhD; Albert E. Jergens, DVM, PhD

Objective—To characterize mucosal gene expression in dogs with chronic enteropathy
(CE).
Animals—18 dogs with CE and 6 healthy control dogs.
Procedures—Small intestinal mucosal biopsy specimens were endoscopically obtained
from dogs. Disease severity in dogs with CE was determined via inflammatory bowel index
scores and histologic grading of biopsy specimens. Total RNA was extracted from biopsy
specimens and microchip array analysis (approx 43,000 probe sets) and quantitative reverse
transcriptase PCR assays were performed.
Results—1,875 genes were differentially expressed between dogs with CE and healthy
control dogs; 1,582 (85%) genes were downregulated in dogs with CE, including neurotensin, fatty acid–binding protein 6, fatty acid synthase, aldehyde dehydrogenase 1 family
member B1, metallothionein, and claudin 8, whereas few genes were upregulated in dogs
with CE, including genes encoding products involved in extracellular matrix degradation
(matrix metallopeptidases 1, 3, and 13), inflammation (tumor necrosis factor, interleukin-8,
peroxisome proliferator–activated receptor γ, and S100 calcium-binding protein G), iron
transport (solute carrier family 40 member 1), and immunity (CD96 and carcinoembryonic
antigen–related cell adhesion molecule [CEACAM] 18). Dogs with CE and protein-losing
enteropathy had the greatest number of differentially expressed genes. Results of quantitative reverse transcriptase PCR assay for select genes were similar to those for microchip
array analysis.
Conclusions and Clinical Relevance—Expression of genes encoding products regulating
mucosal inflammation was altered in dogs with CE and varied with disease severity.
Impact for Human Medicine—Molecular pathogenesis of CE in dogs may be similar to
that in humans with inflammatory bowel disease. (Am J Vet Res 2012;73:1219–1229)

C

hronic enteropathies are a group of disorders that
cause gastrointestinal tract inflammation and persistent or recurrent signs of gastrointestinal tract dis-
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Abbreviations

Crohn’s disease
Chronic enteropathy
Canine inflammatory bowel disease
activity index
Gene ontology
Inflammatory bowel disease
Nuclear factor-κB
Protein-losing enteropathy
Quantitative reverse transcriptase PCR
Ulcerative colitis

ease in dogs. The most common causes include adverse gastrointestinal tract reaction to food, idiopathic
IBD, and antimicrobial-responsive enteropathy.1–4 The
pathogenesis of CE in dogs likely involves several factors including host genetics, intestinal microenvironment (bacteria and diet), immune system function, and
environmental triggers of intestinal inflammation.1,5–7
Strategies for diagnosis of CE include extensive evalua-
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tion of patients to detect underlying diseases and histologic evaluation of intestinal mucosal biopsy specimens
for detection of lymphocytic-plasmacytic, eosinophilic,
or granulomatous inflammation.1,2
Dysregulated gene expression is important in the
pathogenesis of CEs in humans, including IBD.8 Various genes encoding for proteins involved in fatty acid
absorption and synthesis have different levels of expression in the ileum and colon of humans with CD and
UC.9 Results of another study10 in which microchip array analysis of mRNA from mucosal biopsy specimens
was performed indicate genes encoding for enzymes
responsible for detoxification (eg, cytochrome P450)
are downregulated in cells of the colonic mucosa of humans with IBD. Genes encoding for chemokines, markers of neutrophil activation, and anti-inflammatory
factors are upregulated in humans with CE.11,12 Moreover, disturbances in expression of genes encoding for
proteins involved in innate or adaptive immunity, detoxification, and nuclear transcription are important in
the pathogenesis of mucosal inflammation in mice with
experimentally induced colitis.13,14
The objectives of the study reported here were to determine gastrointestinal mucosal gene expression patterns
in dogs with CE, compare results with those for healthy
control dogs, and determine whether gene expression differs among dogs with CE of various severities. In addition,
expression of genes in dogs with CE was compared with
that reported for humans with IBD.
Materials and Methods
Animals—Eighteen dogs with CE were included
in the study. Criteria for selection of dogs with CE
included a history of chronic vomiting, diarrhea, or
weight loss of at least 6 weeks’ duration, exclusion of
identifiable underlying disorders (via performance of a
thorough laboratory diagnostic evaluation), and histopathologic evidence of gastrointestinal mucosal inflammation consistent with a diagnosis of idiopathic CE.
Prior to enrollment, dogs had been fed an elimination
diet exclusively for 3 weeks followed by treatment with
metronidazole (10 mg/kg, PO, q 12 h for 3 weeks); dogs
selected for the study had failed to improve with either
treatment. All medications were discontinued at least
2 weeks before collection of gastrointestinal mucosal
specimens. Disease severity was determined by use of
the CIBDAI,15 which included assessment of the following 6 variables: attitude and activity, appetite, vomiting,
fecal consistency, fecal frequency, and weight loss. After
summation of scores for each of the 6 variables, a total
composite score was determined, which indicated clinically unimportant (score, 0 to 3), mild (score, 4 to 5),
moderate (score, 6 to 8), or severe (score, 9 or greater)
clinical signs of CE.
Six mixed-breed dogs owned by Iowa State University were included in the healthy control group.
Control dogs were judged to be healthy on the basis of
unremarkable physical examination, CBC, serum biochemical analysis, urinalysis, and direct or indirect fecal evaluation (for detection of parasites) results. None
of the healthy control dogs had signs of gastrointestinal
tract disease during the 6 weeks prior to the start of the
study.
1220
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Approval to conduct the study was obtained from
the Iowa State University Institutional Animal Care
and Use Committee. Owners of dogs with CE provided
informed written consent prior to enrollment of those
dogs in the study.
Collection of tissue biopsy specimens—Food
was withheld from dogs for 12 hours prior to collection of tissue specimens. Mucosal biopsy specimens
were endoscopically obtained from the stomach and
duodenum of each dog for histologic examination
as part of a standard esophagogastroduodenoscopy
protocol performed at Iowa State University. Gastric
biopsy specimens were obtained for microscopic
evaluation to detect gastric mucosal inflammation
attributable to causes other than CE (eg, Helicobacter
spp–associated gastritis). Each dog underwent a
standard anesthetic protocol; butorphanol was administered IV as a preanesthetic agent, propofol was
administered IV as an induction agent, and isoflurane
(administered at a concentration of 2% to 3% in oxygen delivered with an inhalation gas delivery system)
was used to maintain anesthesia. Ten to 12 mucosal
biopsy specimens were obtained from the proximal
to middle portions of the duodenum of each dog.
Four mucosal biopsy specimens were obtained from
each colonic segment (ascending, transverse, and
descending) of 4 dogs that underwent colonoscopy.
Colonoscopy was performed in these 4 dogs because
they had clinical signs of enterocolitis with inflammation of both the small and large intestines. Three
duodenal mucosal biopsy specimens from each dog
were placed in a commercial liquid RNA preservativea immediately after collection and kept at −80°C
until isolation of RNA. The remaining specimens
were placed in 10% neutral-buffered formalin, routinely processed, and stained with H&E for histologic evaluation. Sections of intestinal mucosal biopsy
specimens were scored by use of standardized criteria to determine type and amount of inflammatory
cell infiltrate and architectural changes in tissue.16
All intestinal mucosal biopsy specimen sections were
evaluated by a board-certified veterinary pathologist
(MRA) with experience in gastrointestinal pathology.
RNA extraction and cDNA synthesis—Total RNA
was extracted from 2 intestinal mucosal biopsy specimens of each dog by use of a commercial RNA extraction kitb in accordance with the manufacturer’s protocol
for extraction of RNA from animal tissue. Purity and
integrity of RNA were assessed via a bioanalyzer with a
reagent set.c Control samples that did not undergo reverse transcription and had nuclease-free water instead
of RNA were prepared. First-strand cDNA was synthesized by use of random hexamers and oligo(dT) primersd in accordance with the manufacturer’s instructions.
None of the RNA samples had evidence of genomic
DNA after amplification.
Microchip array analysis—Total RNA was transported to the University of Minnesota Biomedical
Genomics Center Microarray Facility for labeling, hybridization, and acquisition of images. Microchip array analysis was performed with an array platform.e
Control samples included 4 spiked control samples for
AJVR, Vol 73, No. 8, August 2012
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labeling (lys, phe, thr, and dap genes of Bacilus subtilis), 4 exogenous spiked control samples for hybridization (bioB, bioC, and bioD genes of E coli and the cre
gene of the P1 bacteriophage), and the housekeeping
genes glyceraldehyde 3-phosphate dehydrogenase and
β-actin for normalization of gene expression data. The
order in which samples were prepared was determined
by use of a computer-generated randomization procedure prior to processing to avoid systematic bias. Hybridization reactions were performed with reagentsf in
accordance with the manufacturer’s instructions and as
previously described.17 After hybridization, microchips
were washed and stained with a streptavidin-conjugated phycoerthyrin dye enhanced with biotinylated goat
anti-streptavidin antibody via a wash and stain stationg
and associated software. Images of microchips were acquired by use of a scanning system.h
The microchip arraye included 43,036 probes to
simultaneously detect approximately 18,000 Canis familiaris mRNA or expressed sequence tag–based transcripts and > 20,000 nonredundant predicted genes.
Sequences in the microchip array were obtained from
C familiaris UniGene build No. 11 (April 2005); GenBank mRNA sequences up to April 15, 2005; and gene
predictionsi from the Boxer genome.j Each RNA sample
from each dog was treated as an individual unit for
analysis.
QRT-PCR assay—To confirm results of microchip
array analysis, some of the genes with > 3.0-fold differences in expression among dogs with CE of various severities were assayed with asymmetric cyanine
dye–based 2-step real-time QRT-PCR assay (Appendix); cDNA prepared from each total RNA sample was
used. Gene-specific primer sets were designed by use of
software,k and at least one of the primers in each primer pair spanned a genomic intron. Target sequences in
cDNA samples were detected with QRT-PCR assay by
use of a dye mixture.l For normalization of data, expression of the canine β-glucuronidase gene was used
as the reference because it had stable expression in intestinal mucosal biopsy specimens obtained from dogs
of all groups.
Prior to analysis of cDNA samples, all QRT-PCR assay gene targets were evaluated on a test plate via serial
dilutions (range, undiluted to 1:100,000) of a mixture
consisting of an equal portion of each of the 24 (6 control and 18 CE dogs) study cDNA samples. Results of
this test plate QRT-PCR assay indicated the cDNA sample dilution range within which quantitative PCR inhibition was absent and within which standard curves for
all targets could be reliably generated. Calculation of results was performed via a spreadsheet softwarem–based
method.18 Test plate QRT-PCR assay results indicated
that the cDNA samples had no quantitative PCR–inhibitory properties, and a common dilution range (1:5 to
1:250 [1.319 to 0.0263 ng of cDNA/µL]) for all target
sequence standard curves was determined by use of the
spreadsheet softwarem–based method.18
Standard curves with 5 data points were generated
for each target sequence within the common dilution
range. Each cDNA sample was diluted to a concentration of approximately 2.8637 ng/µL before performance
of QRT-PCR assays so that addition of 6 µL of cDNA

to each 25-µL assay mixture resulted in a final cDNA
concentration of 0.6873 ng/µL. This concentration value had been calculated via the spreadsheet softwarem–
based method as the mean of the first 2 points of each
target sequence standard curve. The reaction mixture
also contained forward and reverse primers (500nM
each; Appendix), nuclease-free water, 3mM MgCl2,
and 500nM (final concentration) free passive reference dye.n The cDNA samples, control samples without
template sequences, and standard curve samples were
placed in duplicate in wells of 96-well QRT-PCR assay
plates. Plates were placed in a sequence detection systemo and exposed to the following thermoprotocol: 2
minutes at 50°C, 2 minutes at 95°C, 40 cycles of 15
seconds at 95°C, and 30 seconds at 60°C, then melt
curve analysis at 60°C. Cycle values were determined
at an appropriate threshold for each target sequence
by use of software,o and relative quantitative analysis
was performed manually by use of custom spreadsheet
files.m Sample signals determined to have resulted from
primer-dimer formation (on the basis of evaluation of
melt curves) were excluded from data analysis. Cycle
values for each target sequence in each cDNA sample
were interpreted by use of the standard curve for each
of those target sequences. The resulting relative target
sequence expression values were normalized relative
to β-glucuronidase expression. Relative expression
data were calculated by use of an efficiency-corrected
method.19
Statistical analysis—Data from the 24 (6 control
and 18 CE dogs) microchip array analyses were normalized by use of the robust multiarray mean normalization method.20 For each of the approximately 43,000
probe sets on the microchip array, a standard permutation test was applied to the normalized data to test
for differences in distribution of target sequence expression between healthy control dogs and dogs with
CE. Permutation tests yielded a P value for each of the
probe sets. These P values were converted to q values
as previously described.21 Genes that had different expression between groups of dogs and an estimated false
discovery rate of 1% (q < 0.01) were identified. Only
results for probe sets having an estimated ≥ 2-fold difference in expression between groups of dogs were
evaluated further.
A Fisher exact test was used to identify GO terms
that were overrepresented among the probe sets for
genes that were determined to have different expression
between groups of dogs. One test for overrepresentation was conducted for each of the GO terms that was
associated with probe sets with statistically significant
results; GO annotation information was provided by
the microarray chip manufacturer.p Functional attributions of genes were determined via a databaseq with the
default parameters.
To determine whether gene expression was associated with severity of clinical disease, microchip array
analysis results for 17 genes that had > 3.0-fold differences in expression among dogs with CE of various
severities (on the basis of CIBDAI values) were statistically compared. These genes included chemokine
ligand 13, aldehyde dehydrogenase 1 family member
B1, metallothionein, tachykinin precursor 1, solute car-
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Figure 1—Photomicrographs of representative small intestinal mucosal biopsy specimens endoscopically obtained from dogs with
CE. A—Notice moderate diffuse lymphocytic-plasmacytic infiltration in the lamina propria and marked dilation of 2 crypts that contain eosinophilic material, numerous neutrophils, and cell debris
(crypt abscess). These crypts are lined by thin elongate cells. B—
Notice severe villous atrophy and lymphocytic-plasmacytic enteritis. Intestinal villi are short and wide, and some have dilated lacteals surrounded by dense infiltrates of lymphocytes and plasma
cells. Numerous intraepithelial lymphocytes are present. C—Notice a focally extensive mucosal ulcer covered by neutrophils and
cell debris. There is a dense infiltrate of lymphocytes, plasma cells,
and macrophages deep to the ulcer. H&E stain; bars = 200 µm.

rier family 40 member 1, RNase A family 1, caspase 3,
CD96 molecule, granzyme B, matrix metallopeptidase
1, fatty acid–binding protein 6, glucagon, claudin 8,
S100 calcium-binding protein G, cell division cycle associated 3, peroxisome proliferator–activated receptor
γ, and neurotensin. An ANOVA overall F test was used
to identify significant differences among results for
dogs with various severities of CE (dogs with moderate
CE, dogs with severe CE but not PLE, dogs with PLE)
and healthy control dogs; this was intended to identify
associations between gene expression and disease severity. This analysis was performed separately for each gene.
Then, pairwise comparisons were performed between
gene expression values for each group of dogs for genes
with an overall F test value that was significant (P < 0.05).
Gene expression in mucosal biopsy specimens
obtained from dogs with CE in the present study determined with microchip array analysis was compared
with expression of genes in humans with IBD determined in other studies. Results of gene expression profiles in humans with CD or UC were obtained via literature searches for manuscripts published from 1998
through 2010.
Results
Demographics and clinical characteristics of
dogs—Of the 18 dogs with CE, 8 were males (3 sexually intact and 5 neutered) and 10 were females (1 sexually intact and 9 neutered). Mean age of these dogs was
1222
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7.2 years (range, 3 to 11 years). Breeds included mixed
(n = 5), German Shepherd Dog (2), and 1 each of Australian Shepherd Dog, Cocker Spaniel, English Bulldog,
Labrador Retriever, Jack Russell Terrier, Gordon Setter,
Keeshond, German Shorthair Pointer, Yorkshire Terrier,
Shih Tzu, and Beagle. All dogs with CE had moderate
(n = 10) to severe (8) disease; mean CIBDAI score was
7.8 (range, 6 to 12). Five of the 8 dogs with severe CE
had panhypoproteinemia (mean serum albumin concentration, 1.7 g/dL [range, 1.2 to 1.9 g/dL]; mean total protein concentration, 3.5 g/dL [range, 3.0 to 3.9
g/dL]), which was consistent with a diagnosis of PLE;
these dogs had a mean CIBDAI score of 8.6. Abnormalities of duodenal mucosa (ie, increased granularity, friability, or erosions) were endoscopically observed in all
18 dogs with CE. Four of these dogs also underwent
colonoscopy; each of these dogs had colonic erosions
and areas of colonic mucosa that were friable. Histologic examination of intestinal mucosal biopsy specimens
indicated 8 dogs had mild and 10 dogs had moderate to
severe inflammatory lesions (Figure 1).
Mean age of the 6 healthy control dogs was 4.3
years (range, 3 to 6 years). Results of laboratory tests,
endoscopic examinations, and histologic examination
of mucosal biopsy specimens obtained from these control dogs were unremarkable.
Gene expression determined via microchip array—Target gene expression was significantly different between healthy control dogs and dogs with CE for
1,875 of the probe sets. Healthy control dogs and dogs
with CE had significantly different expression of genes
associated with protein synthesis and transport, cell
replication, intracellular organelles, and extracellular
matrix degradation (data not shown). Selective filterAJVR, Vol 73, No. 8, August 2012
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Table 1—Expression of select genes in intestinal mucosal biopsy specimens endoscopically obtained from 18 dogs with CE as
determined with microchip array analysis.
			
Gene name
Abbreviation
Function of protein

Fold difference
in expression*

RNase A family 1
Ribonucleic acid SE1
RNA hydrolysis
Matrix metallopeptidase 1
MMP1
Extracellular matrix degradation
S100 calcium-binding protein G
S100G
Calcium transport and activity
Solute carrier family 40 member 1
SLC40A
Iron transport
Peroxisome proliferator–activated receptor γ
PPARG
Regulates NF-κβ pathway
Tumor necrosis factor
TNF
Promotes inflammation
Interleukin-8
IL-8
Induces chemotaxis
			
CD96 molecule
CD96
Adaptive and innate immunity
Caspase 3
CASP3
Cellular apoptosis
Granzyme B
GZMB
Cytotoxic T lymphocyte–mediated apoptosis
Neurotensin
NTS
Neuropeptide signaling
Glucagon
GCG
Counters insulin, cell proliferation
Aldehyde dehydrogenase 1
ALDH1B1
Metabolizes alcohol
family member B1
Regenerating islet-derived 3 gamma
REG3G
Promotes inflammation
			
Fatty acid–binding protein 6
FABP6
Fatty acid uptake and transport
Tachykinin precursor 1
TAC1
Gastrointestinal tract neuropeptide
Metallothionein
MTIE
Barrier function
Claudin 8
CLDN8
Tight junction protein
Chemokine ligand 13
CXCL13
B-cell chemoattractant
Cell division cycle associated 3
Centers for Disease Control and
Promotes mitosis
Prevention A3
Fatty acid synthase
FASN
Fatty acid synthesis

57
11
11
11
4
3
3
3
3
3
–92
–67
–16
–8
–13
–8
–7
–6
–4
–4
–3

*Results are expressed relative to expression of genes in intestinal mucosal biopsy specimens endoscopically obtained from 6 healthy control
dogs. Expression of all genes listed is significantly (P < 0.05) different between dogs with CE and healthy control dogs.
Table 2—Results of pairwise comparisons of gene expression in intestinal mucosal biopsy specimens
endoscopically obtained from 18 dogs with CE of various severities and 6 healthy control dogs.
		 Pairwise comparison
Gene

Abbreviation

PC

PS

PM

SC

Chemokine ligand 13
CXCL13
< 0.001*
0.03*
0.04*
0.04*
Aldehyde dehydrogenase 1
ALDH1B1
< 0.001*
0.03*
0.05
0.10
family member B1
Metallothionein
MT1E
< 0.001*
0.03*
0.04*
0.08
Tachykinin precursor 1
TAC1
< 0.001*
0.03*
0.03*
0.07
Solute carrier family 40
SLC40A
< 0.001*
0.03*
0.04*
0.11
member 1
RNase A family 1
Ribonucleic acid SE1 < 0.001*
0.03*
0.04*
0.09
					
Caspase 3
CAP3
0.002*
0.11
0.16
0.24
CD96 molecule
CD96
0.008*
0.27
0.10
0.19
Granzyme B
GZMB
0.03*
0.56
0.08
0.20
Matrix metallopeptidase 1
MMP1
0.005*
0.03*
0.06
0.73
Fatty acid–binding protein 6
FABP6
< 0.001*
0.07
0.25
0.09
Data are P values for pairwise comparisons of expression of genes. Results for 17 genes with > 3.0fold different expression among dogs with CE of various severities (moderate CE, severe CE but not PLE,
and PLE; determined by use of the CIBDAI15) were compared. Genes with significantly (P < 0.05) different
expression among dogs with various severities of CE and healthy control dogs were selected for further
analysis. Expression of these genes was compared in a pairwise manner between groups of dogs.
*Expression of gene is significantly (P < 0.05) different between the groups of dogs for which results are
compared in the column.
PC = Dogs with PLE versus healthy control dogs. PM = Dogs with PLE versus dogs with moderate CE. PS =
Dogs with PLE versus dogs with severe CE but not PLE. SC = Dogs with severe CE but not PLE versus healthy
control dogs.

ing (fold enrichment ≥ 1.3 and false discovery rate <
1%) of genes indicated that expression of most differentially expressed genes was lower in intestinal mucosal
biopsy specimens obtained from dogs with CE versus
those obtained from healthy control dogs. Of the 1,875
genes, expression of 1,582 (84%) was lower in intestinal mucosal biopsy specimens obtained from dogs with
CE versus those obtained from healthy control dogs, including genes with annotations indicating associations
with mucosal homeostasis, mitosis and cell cycle, and

cell-to-cell signaling. Few genes had significantly higher expression in mucosal biopsy specimens obtained
from dogs with CE versus those obtained from control
dogs; these included genes encoding for the matrix metallopeptidases and proteins associated with inflammation and immune function.
Results for select genes with significantly different
expression between dogs with CE and healthy control
dogs were summarized (Table 1). Neurotensin was the
most highly downregulated (compared with expression
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Figure 2—Mean ± SEM expression of select genes in intestinal mucosal biopsy samples endoscopically obtained from 18 dogs with
CE (light gray bars) and 6 healthy control dogs (dark gray bars). Values were determined via QRT-PCR assay. Expression values are normalized relative to expression of β glucuronidase. Expression of each of the genes is significantly (P < 0.05) different between groups
of dogs. ANP32 = ANP32 family member A. CASP3 = Caspase 3. CLCN = Chloride channel 3. FBL = Fibrillarin. GZMB = Granzyme B.
MMP1 = Matrix metallopeptidase 1.
Table 3—Comparison of gene expression in dogs with CE in the present study versus that in humans with IBD* reported by other
authors.
				
				
Gene function and abbreviation
Name of gene
Type of IBD
References

Relative gene
expression in
dogs with CE†

Immune and inflammatory response				
CD96
CD96 molecule
CDa
63
3
IL-8
Interleukin-8
CD and UC
8 and 63
3
c
c
TNF
Tumor necrosis factor
CD and UC
60 and 62
3
CXCL13
CXCL13
—
—
–4
a
PPARG
Peroxisome proliferator–activated receptor γ
CD
63
4
				
Cell proliferation and growth				
REG3G
Regenerating islet-derived 3 gamma
UC
8 and 60
–8
Ribonucleic acid SE1
RNase family genes
UC
8
57
GCG
Glucagon
CD
8 and 63
–67
Centers for Disease Control and
Cell division cycle associated protein 3
—
—
–4
Prevention A3
S100G
S100 calcium-binding protein G
CD and UC
8 and 63
11
CASP3
Caspase 3
—
—
3
c
GZMB
Granzyme B
CD
61
3
				
Cell structure and permeability				
MT1E
Metallothionein 1E
UC
8
–7
MT2A
Metallothionein 2A
CDa,c
63
–5
MMP1
Matrix metallopeptidase 1
CD and UC
8 and 63
11
MMP3
Matrix metallopeptidase 3
CD and UC
8 and 60
3
b,c
MMP13
Matrix metallopeptidase 13
UC
64
4
a
CLDN8
Claudin 8
CD
58
–6
				
Metabolic pathways and transport				
SLC40A
Solute carrier family 40 member 1
CDa
54
11
ALDH1B1
Aldehyde dehydrogenase 1 family member B1
CDa
58 and 63
–16
FABP6
Fatty acid–binding protein 6
CD and UC
9 and 58
–13
—
Fatty acid synthase
CD and UC
9
–3
a
CPO
Carboxypeptidase
CD
58
–7
				
Neuropeptide signaling				
NTS
Neurotensin
CDa
58
–92
TAC1
Tachykinin precursor 1
—
—
–8
Data are comparisons of mRNA expression values unless otherwise indicated.
*Genes with increased or decreased expression in humans with CD or UC. †Results are expression of genes in dogs with CE relative to
expression in humans with IBD.
— = Not applicable.
a
Gene expression results only for humans with CD. bGene expression results only for humans with UC . cResults are for protein expression.
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in healthy control dogs) gene in dogs with CE (expression 92-fold as low). Other genes significantly downregulated in dogs with CE included glucagon (expression 67-fold as low), aldehyde dehydrogenase 1 family
member B1 (18-fold as low), and fatty acid–binding
protein 6 (15-fold as low). Both metallothionein 1E
and metallothionein 2A genes were downregulated (expression 7- and 5-fold as low, respectively) in CE dogs,
compared with gene expression in control dogs. Genes
with significantly higher expression in dogs with CE
versus healthy control dogs included RNase A family
1 (expression 57-fold as high) and matrix metallopeptidase 1, solute carrier family 40 member 1, and the
S100 calcium-binding protein family of genes including
S100G, S100A2, and S100A10 (11-, 2-, and 2-fold as
high, respectively).
Gene expression in dogs with various severities
of CE—Seventeen genes were ˃ 3.0-fold differentially
expressed (as determined with microchip array analysis) among healthy control dogs and dogs with moderate CE, severe CE but not PLE, and PLE. Of these 17
genes, expression for 11 was significantly (P < 0.02)
different among the 4 groups of dogs. Significant differences in expression were detected among dogs with
PLE and those with moderate or severe CE on the basis of CIBDAI scores (Table 2). Dogs with PLE had
the highest CIBDAI scores; these dogs had the highest
number of genes with significantly different expression
in mucosal biopsy specimens, compared with that in
healthy control dogs (n = 11 genes), dogs with severe
CE but not PLE (7), and dogs with moderate CE (5).
In contrast, only 1 gene was differentially expressed in
mucosal biopsy specimens obtained from dogs with severe CE that did not have PLE versus those obtained
from healthy control dogs.
Gene expression determined via QRT-PCR
assay—Quantitative reverse transcriptase PCR assay
was performed to determine expression of select genes
for which significantly different expression was detected between healthy control dogs and dogs with CE on
the basis of microchip array analysis. Six genes of interest were selected on the basis that different levels of expression between groups of dogs had been detected via
microchip array analysis (acidic [leucine-rich] nuclear
phosphoprotein 32 family member A and fibrillarin),
genes encoded for cell-surface molecules (granzyme B,
caspase 3, and chloride channel 3), or the genes encoded for molecules with a putative role in mediating
intestinal inflammation (granzyme B, caspase 3, and
matrix metallopeptidase 1). Results of QRT-PCR assay
for these genes were consistent with results of microchip array analysis (Figure 2).
Gene expression in dogs with CE versus that in
humans with IBD—Twenty-one of the 25 genes with
the greatest difference in expression between dogs with
CE and healthy control dogs are upregulated or downregulated in humans with IBD (Table 3). Four of the
genes with significantly different expression between
dogs with CE and healthy control dogs (CXCL13,
cell division cycle associated protein 3, caspase 3, and
tachykinin precursor 1) are not differentially expressed

in humans with CD or UC. Of the genes that are
upregulated in humans with IBD, CD96 molecule, interleukin-8, tumor necrosis factor, peroxisome proliferator–activated receptor γ, RNase A family 1, S100 calcium-binding protein G, caspase 3, granzyme B, matrix
metallopeptidase 1, matrix metallopeptidase 3, matrix
metallopeptidase 13, and solute carrier family 40 member 1 were upregulated in dogs with CE. Conversely, 9
of the 21 genes upregulated in humans with IBD were
downregulated in dogs with CE.
Discussion
Dogs that are genetically predisposed to the most
prevalent forms of CE, including idiopathic IBD, have
aberrant immune responses and dysbiotic microbiota.1,3,5,7,22 Chronic enteropathies in dogs are associated
with abnormalities in mucosal immune cell populations and cytokine expression, activation of NF-κB,
and histopathologically detectable intestinal inflammation.1,4,23–27 Results of a recent study22 indicate intestinal inflammation is associated with a shift in the
most prevalent intestinal microbes from gram-positive
Firmicutes (eg, order Clostridiales) to gram-negative
bacteria (predominantly Proteobacteria [including Enterobacteriaceae]). Granulomatous colitis in Boxers is
associated with invasive Escherichia coli that are similar to mucosally adherent and invasive E coli associated
with intestinal inflammation in humans.28 Furthermore, the findings of other investigators that mucosal
expression of Toll-like receptor-2, -4, and -9 is upregulated in various breeds of dogs29 and that German Shepherd Dogs with CE have polymorphisms of Toll-like
receptor-55 indicate that interaction between intestinal
microbes and the innate immune system is important.
Thus, it was our intent to evaluate intestinal mucosal
gene expression patterns in dogs with CE to identify
genes that might be involved in CE disease mechanisms
and to compare results with those reported for humans
with IBD.
Results of microchip array analysis in the present
study indicated that expression of > 1,870 genes was
significantly different between healthy control dogs and
dogs with CE. The functional importance of these differences in gene expression was determined by use of
annotation-based GO databases. Results of initial GO
analysis indicated that 42 biological process terms, 30
cellular components, and 18 molecular function terms
were significantly overrepresented (false discovery rate
≤ 1%) among the genes determined to have different
expression between dogs with CE and healthy control
dogs (data not shown). Bioinformatics resourcesp were
used in addition to this computational procedure to
determine biologically important differences between
gene expression in dogs with CE versus that in healthy
control dogs.13,30
Results indicated that a majority (1,582 of 1,875
[84%]) of differentially expressed genes were downregulated (rather than upregulated) in dogs with CE
in the present study. Neurotensin was the most highly
downregulated gene in these dogs. Upregulation of
neurotensin is associated with acute inflammation in
humans with IBD and repair of injured epithelium (via
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stimulation of expression of epithelial growth factor receptor) in rats and mice with experimentally induced
colitis.31,32 Glucagon and cell division cycle associated
A3 protein have roles in cellular replication via different mechanisms. The cell division cycle-associated A3
gene in humans encodes a protein that is required for
controlled entry of cells into mitosis; this protein has
not been identified in dogs.33 Glucagon-like peptide-2,
a product of posttranslational processing of proglucagon in the intestine, has intestinal growth-promoting
properties.34 Results of another study35 indicate that
glucagon-like peptide-2 attenuates intestinal inflammation in rodents with experimentally induced IBD,
suggesting a potential role for this peptide in treatment
of IBD in humans. It is possible that dogs with CE in
the present study may have had low intestinal mucosal concentrations of glucagon-like peptide-2, which
may have contributed to impaired intestinal protection
against and repair following mucosal damage.
Fatty acids have an important role in inflammatory
processes via nutritional and protective effects on enterocytes.36 Results of another study9 indicate that genes
involved in expression of fatty acid transport, fatty acid
binding, fatty acid acetylation, and fatty acid synthesis
proteins are downregulated in ileal and colonic tissues
of humans with CD and UC. Findings of the present
study that expression of fatty acid–binding protein 6
and fatty acid synthase were 13-fold and 3-fold as low,
respectively, in intestinal mucosal biopsy specimens obtained from dogs with CE as in biopsy specimens obtained from healthy control dogs indicated dogs with
CE had alterations in fatty acid metabolism similar to
those detected in humans with IBD.
Intestinal epithelial barrier function is impaired in
animals with IBD.13,37,38 Expression of several genes associated with maintenance of the intestinal epithelial
barrier, including metallothionein 1E, metallothionein
2A, and claudin 8, was downregulated in dogs with CE
in the present study. Metallothioneins play a central role
in zinc homeostasis, modulate activation of the nuclear
transcription factor NF-κB, and serve as antioxidants to
reduce intestinal inflammation.39,40 Claudins are a family of proteins that contribute to intestinal barrier function as components of tight junction strands between
intestinal epithelial cells.41 Changes in expression and
distribution of claudin 8 have been detected in humans with active CD and lead to altered tight junction
structure and barrier dysfunction.42 Results of other
studies43,44 indicate expression of matrix metallopeptidases in intestinal mucosa of IBD patients is a marker
of disease activity, and these enzymes may be targets
for treatment. Matrix metallopeptidases are involved
in tissue remodeling, angiogenesis, and leukocyte extravasation in inflamed intestinal mucosa in humans
with CD or UC.45 Many of the matrix metallopeptidases
investigated in those studies were also upregulated in
dogs with CE in the present study, in particular matrix
metallopeptidases 1, 3, and 13.
Numerous immune and inflammatory response
genes were upregulated in dogs with CE in the present study. Members of the S100 calcium-binding protein family of genes are overexpressed in humans with
IBD,8 and higher expression of S100 calcium-binding
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protein G, S100 calcium-binding protein A2, and S100
calcium-binding protein A10 was detected in dogs with
CE versus healthy control dogs in the present study.
Moreover, expression of carcinoembryonic antigen–
related cell adhesion molecule 18 (a marker of neutrophil activation and regulator of T-cell function) was
also increased in dogs with CE, which suggested that
there was infiltration of neutrophils in intestinal lesions, possibly in response to intestinal microbes.46 The
peroxisome proliferator–activated receptor γ gene encodes for a nuclear hormone receptor that regulates intestinal inflammation via antagonism of the transcription factor NF-κB.47 Peroxisome proliferator–activated
receptor γ is highly expressed in a variety of cell types
involved in intestinal inflammation, including monocytes, macrophages, T cells, dendritic cells, and intestinal epithelial cells. Increased epithelial expression of
this protein is associated with attenuation of inflammatory intestinal lesions in experimentally induced IBD in
mice.48 It is possible that upregulated expression of this
gene in dogs with CE in the present study was attributable to a compensatory response to chronic mucosal
inflammation.
The finding of the present study that the caspase 3
and granzyme B genes were overexpressed in dogs with
CE indicated that apoptotic mechanisms may have been
involved in pathogenesis of the disease in those dogs.
Resistance of T cells against apoptosis may contribute
to persistent intestinal inflammation in humans with
IBD.49 Granzyme B is a serine protease that is an important mediator of apoptosis of cells targeted by natural
killer cells and cytotoxic CD8+ lymphocytes. The primary apoptotic mechanism of action of granzymes is
perforin-mediated cytotoxicity.50 Further investigation
of the mechanisms controlling mucosal lymphocyte
apoptosis in dogs with CE is warranted.
Several organic cation transporter genes, including
solute carrier family 40 member 1 and solute carrier
family 2, member 2 (SLC2A2) were overexpressed in
dogs with CE in the present study. Solute carrier membrane transport proteins are diverse, are expressed
in most mammalian cells, and transport charged and
uncharged organic molecules and inorganic ions.
Solute carrier family 40 member 1 is involved in basolateral iron transport, and members of solute carrier family 2 SLC2, which includes 14 proteins, are
facilitated glucose transporters.51 Other organic cation
transporter genes (solute carrier family 22, member 4
[SLC22A4], also known as organic cation transporter
gene 1 [OCTN1]; and solute carrier family 22, member 5
[SLC22A5], also known as organic cation transporter
gene 2 [OCTN2]) are expressed in epithelial cells and
have been implicated in CD.52
The present study had some limitations. Gene expression was assessed in mucosal biopsy specimens
obtained at only 1 time from each dog; results provided evidence that expression of genes in dogs with
CE was different from that in healthy control dogs only
at the time CE was diagnosed. Results of future studies in which mucosal gene expression is determined at
multiple times after diagnosis of CE in dogs may better
elucidate the importance of specific patterns of gene expression in onset and progression of the disease. Also,
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several of the significant differences in expression of
genes between dogs with CE and healthy control dogs
in the present study may be attributable to secondary,
rather than primary, abnormalities of gene expression
related to pathogenesis of CE. We chose to include a
group of control dogs with no signs of gastroenteritis
that were younger than the dogs with CE. The strict
inclusion criteria for control dogs in the present study
(dogs that were free of disease and had unremarkable
results of diagnostic tests) resulted in inclusion of a
small number of such dogs. However, inclusion of
healthy control dogs of mixed breeds was considered
preferable to inclusion of age-matched Beagles bred for
use in research; such Beagles sometimes have evidence
of intestinal disease.53 Therefore, it is possible that some
of the differences in gene expression were attributable
to differences in age between the 2 groups of dogs. Nevertheless, the tissue sampling and microchip array analysis methods used in the present study yielded results
that indicated patterns of gene expression in dogs with
CE were broadly similar to those in humans with IBD,
including expression of genes regulating immune and
inflammatory responses, metabolism, cell proliferation,
and epithelial structure and function.8,54–62
Results of the present study indicated that the expression of multiple genes regulating mucosal inflammation was markedly altered in dogs with CE, compared with that in healthy control dogs. The differential
expression of several genes (fatty acid–binding protein
6, metallothionein 1E, claudin 8, matrix metallopeptidase 1, peroxisome proliferator–activated receptor
γ, S100 calcium-binding protein G, and solute carrier
family 40 member 1) between groups of dogs in the
present study indicated that the molecular pathogenesis of CE in dogs may be similar to that in chronic
immune-mediated intestinal inflammation in humans
with IBD. Future experiments that include dogs with
naturally developing IBD may be warranted because genomic sequences of dogs and humans are highly similar63 and longitudinal studies (eg, clinical trials) might
be easily conducted.
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Appendix
Primer sequences used for QRT-PCR amplification of mRNA of various genes in intestinal mucosal
biopsy samples endoscopically obtained from 18 dogs with CE and 6 healthy control dogs.
			
Gene
Primer
Probe sequence (5′ to 3′)
Granzyme B
Glucuronidase β
ANP 32 family member A
Chloride channel 3
MMP13
Caspase 3
Fibrillarin

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

TGT TAX TGC TGC TTG AGA GGA AGG
ACC TGC GTA TCT TGG CCT CAA TCT
ATG CTG GTC CAG AGC TAC AGC AAT
ATG GGT GAT TCT TAT CCC GAC GCA
AAC AGG ACG CCC TCT GAT GTG AAA
TGA GGT GAG GCC TAC GTT GAT TGT
AGA AGG TCC TGG CTC GTA CAT CAT
CCA GGG AAA CAG CAA GAA AGG CAA
GAC AGA TTC TTC TGG CGA TTG CAT CC
TAT GCA GCA TCG ATA CGG TTG GGA
ATT ATT CAG GCC TGC CGA GGT ACA
TAC AAG AAG TCC GCT TCG ACT GGT
TGC TCA TAG CAA TGG TGG ACG TGA
TAC GAA GGA AGG TGT GGG CAT TCA

GenBank
accession No.
NC_006590
NC_006588
NC_006612
NC_006607
NC_006587
NC_006598
NC_006583
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